Clinical reference Biomarker Directory
Back to directory

IgE

Established

IgE is central to allergy diagnosis and directly determines dosing eligibility for the biologic drug omalizumab.

Also known as Immunoglobulin E total IgE
In plain language

IgE drives allergic reactions, and its level in the blood determines dosing for a major asthma biologic drug. A real gap exists though: many patients with severe asthma have IgE levels higher than the official dosing charts cover, even though evidence suggests the drug still helps them.

Biomarker & context

Immunoglobulin E (IgE) mediates allergic and anti-parasitic immune responses; total and allergen-specific IgE testing is central to diagnosing and managing allergic disease, including severe asthma.

What it indicates

Elevated total IgE supports an allergic/atopic phenotype and, in severe asthma, determines eligibility for omalizumab, an anti-IgE biologic; allergen-specific IgE identifies particular triggers (foods, pollens, medications).

Diagnosis & clinical testing

Measured via serum immunoassay; omalizumab dosing is calculated directly from baseline IgE level and body weight using manufacturer dosing tables.

Guiding treatment

A real access gap exists: official omalizumab dosing tables only cover patients up to 1,500 IU/mL (EU) or 700 IU/mL (US), while many severe asthma patients have higher levels, leaving them technically outside labeled dosing guidance despite growing off-label evidence supporting treatment anyway.

Clinical significance

A real treatment-access gap exists for patients with IgE levels above current official dosing table limits.

References
  1. PMC. (2023). Omalizumab for the treatment of patients with severe allergic asthma with IgE levels above >1500 IU/mL.